Figure 1
Rectal temperature (°C) variation according to the circadian time (1, 5, 9, 13, 17 and 21 HALO) of VPA administration (850 mg / kg,i.p.) in a total of 90 mice on day 1 before treatment, and on days 3, 5, 9 and 15 following treatment in surviving mice. Differences related to both dosing-time and sampling-day were statistically validated by one-way ANOVA (p ≤ 0.01).
Figure 2
Body weight loss variation (%) according to the days after VPA-administration in a total of 90 mice. Results are expressed as mean percent change ± S.D and were statistically validated by one-way ANOVA (p ≤0.01).
Figure 3
Body weight loss variation (%) according to the circadian dosing-time of VPA in a total of 90 mice. Results are expressed as mean percent change ± S.D. Statistically significant differences between mean values at least and highest body weight losses were validated by one-way ANOVA (p ≤ 0.01).
Figure 4
Circadian variation in tolerance to VPA (850 mg/kg,i.p.) as assessed by the survival rate at each of six circadian dosing-times (1, 5, 9, 13, 17, and 21 HALO) in a total of 90 mice. Results are expressed as mean percent change ± S.D and were statistically validated by χ 2 test (p ≤ 0.001).